Item 8.01 Other Events.
On
The offering is being made pursuant to the Company's shelf registration
statement on Form S-3 (Registration Statement No. 333-257691) which became
automatically effective upon filing with the
The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement.
The foregoing description of the Underwriting Agreement is not complete and is
qualified in its entirety by reference to the full text of the Underwriting
Agreement, a copy of which is filed as Exhibit 1.1 to this report and is
incorporated by reference herein. A copy of the opinion of
The Company issued press releases on
***
Avidity cautions you that statements included in this report that are not a
description of historical facts are forward-looking statements. These
forward-looking statements include statements regarding the completion of the
offering and the expected net proceeds therefrom. The inclusion of
forward-looking statements should not be regarded as a representation by Avidity
that any of these results will be achieved. Actual results may differ from those
set forth in this report due to the risks and uncertainties associated with
market conditions and the satisfaction of customary closing conditions related
to the offering, as well as risks and uncertainties inherent in Avidity's
business, including those described in the Company's other filings with the
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits Exhibit Number Description 1.1 Underwriting Agreement, datedAugust 3, 2021 , by and amongAvidity Biosciences, Inc. andCowen and Company, LLC ,SVB Leerink LLC ,Evercore Group L.L.C. , andWells Fargo Securities, LLC , as representatives of the several underwriters named therein 5.1 Opinion ofLatham & Watkins LLP 23.1 Consent ofLatham & Watkins LLP (included in Exhibit 5.1) 99.1 Press Release datedAugust 2, 2021 99.2 Press Release datedAugust 3, 2021 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source